Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fedratinib Administered via NG Tube or Dispersed in Healthy Adults
NCT05051553Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fedratinib in myelofibrosis (MF) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration up to 12 days, Area Under the Curve from Time Zero to Last Quantifiable Concentration up to 12 days and 1 more. Started Sep 2021; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05051553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051553.